The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://neilkfec663544.vidublog.com/37862120/glp-3-retatrutide-a-comparative-analysis